Background For patients with pancreatic ductal adenocarcinoma (PDAC), surgical resection
remains the only potentially curative treatment. Surgery is generally followed by …

To evaluate the effectiveness of nab-paclitaxel plus gemcitabine (NG) as a first-line
treatment for advanced pancreatic cancer. A meta-analysis was performed to assess the …

Methods In this single-center retrospective study, 100 BRPC patients treated with
neoadjuvant chemotherapy and resection from 2008 to 2018 were reviewed. Clinical …

Background There is no agreed upon standard of care for borderline‐resectable pancreatic
cancer (BRPC) or locally‐advanced pancreatic cancer (LAPC) patients regarding the benefit …

Pancreatic ductal adenocarcinoma (PDAC) is characterized by heightened autophagy and
systemic immune dysfunction. Modest improvements in clinical outcomes have been …

Introduction: Pancreatic cancer is highly fatal and its incidence is rising worldwide. Its poor
prognosis is attributed to a lack of effective diagnostic and therapeutic strategies …

Objectives To determine the correlation between CT-diagnosed extra-pancreatic extension
of pancreatic ductal adenocarcinoma (PDAC), pathology-diagnosed extra-pancreatic …

Background Neoadjuvant therapy (NAT) is considered a potential approach to improve
survival for patients with pancreatic adenocarcinoma (PA). The objective of this study was to …

Neoadjuvant therapy (NAT)+ surgical resection for pancreatic cancer (PC) has gained
consensus in recent years. Pathological response (PR) is generally assessed according to …

The incidence of pancreatic cancer has been rising worldwide, and its clinical diagnosis and
treatment remain a great challenge. To present the update and improvements in the clinical …